Laboratory Corporation of America Holdings (NYSE:LH) Director R Sanders Williams sold 3,100 shares of the firm’s stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $156.88, for a total value of $486,328.00. Following the transaction, the director now owns 10,073 shares in the company, valued at $1,580,252.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Laboratory Corporation of America Holdings (NYSE LH) traded up 0.17% during trading on Tuesday, hitting $156.76. The stock had a trading volume of 373,634 shares. The company has a market capitalization of $15.96 billion, a price-to-earnings ratio of 21.96 and a beta of 0.94. The stock has a 50 day moving average price of $155.49 and a 200 day moving average price of $144.59. Laboratory Corporation of America Holdings has a 12-month low of $119.51 and a 12-month high of $164.22.

Laboratory Corporation of America Holdings (NYSE:LH) last released its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.47 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.40 by $0.07. The firm had revenue of $2.50 billion for the quarter, compared to analysts’ expectations of $2.47 billion. Laboratory Corporation of America Holdings had a net margin of 7.57% and a return on equity of 16.85%. The business’s revenue was up 4.9% on a year-over-year basis. During the same period in the prior year, the firm earned $2.36 EPS. Equities research analysts forecast that Laboratory Corporation of America Holdings will post $9.51 earnings per share for the current year.

WARNING: “Laboratory Corporation of America Holdings (LH) Director Sells $486,328.00 in Stock” was published by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/08/15/laboratory-corporation-of-america-holdings-lh-director-sells-486328-00-in-stock.html.

Several research firms have weighed in on LH. Barclays PLC raised their target price on Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the company an “overweight” rating in a report on Thursday, July 27th. Zacks Investment Research upgraded Laboratory Corporation of America Holdings from a “sell” rating to a “hold” rating in a report on Thursday, July 27th. BidaskClub lowered Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a report on Friday, June 9th. Credit Suisse Group AG lowered Laboratory Corporation of America Holdings to a “hold” rating and set a $146.00 target price on the stock. in a report on Thursday, July 13th. They noted that the move was a valuation call. Finally, Craig Hallum restated a “buy” rating and set a $179.00 target price (up from $157.00) on shares of Laboratory Corporation of America Holdings in a report on Thursday, July 27th. Seven research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $159.00.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Diversified Trust Co boosted its position in Laboratory Corporation of America Holdings by 2.3% in the first quarter. Diversified Trust Co now owns 2,181 shares of the medical research company’s stock valued at $313,000 after buying an additional 50 shares in the last quarter. State of Alaska Department of Revenue boosted its position in Laboratory Corporation of America Holdings by 43.2% in the first quarter. State of Alaska Department of Revenue now owns 19,536 shares of the medical research company’s stock valued at $2,802,000 after buying an additional 5,898 shares in the last quarter. Quantitative Systematic Strategies LLC boosted its position in Laboratory Corporation of America Holdings by 32.8% in the first quarter. Quantitative Systematic Strategies LLC now owns 5,399 shares of the medical research company’s stock valued at $775,000 after buying an additional 1,334 shares in the last quarter. Coastline Trust Co boosted its position in Laboratory Corporation of America Holdings by 57.4% in the first quarter. Coastline Trust Co now owns 3,810 shares of the medical research company’s stock valued at $547,000 after buying an additional 1,390 shares in the last quarter. Finally, DnB Asset Management AS bought a new position in Laboratory Corporation of America Holdings during the first quarter valued at $9,264,000. 91.64% of the stock is currently owned by hedge funds and other institutional investors.

Laboratory Corporation of America Holdings Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.